CD274 and neoplasm: PD-1/PD-L1 inhibitors, which enhance T cell immunity to impede tumor immune evasion, are considered one of the most successful cancer immunotherapy approaches [60] used in a variety of cancer treatments, such as non-small cell lung cancer (NSCLC) [61], Hodgkin’s lymphoma [62], and melanoma [63].